US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexaria Bioscience Corp

0.2022

-0.0378-15.75%

Volume:104.00

Turnover:21.02

Market Cap:1.03M

PE:- -

High:0.2022

Open:0.2022

Low:0.2022

Close:0.2400

Loading ...

Overview Company News Filings

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

ACCESS Newswire

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

ACCESS Newswire

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

ACCESS Newswire

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

ACCESS Newswire

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

ACCESS Newswire

Lexaria Releases Annual Letter from the CEO

ACCESS Newswire

LEXX: IRB Approval Clears Way for GLP-1 Study #5

Zacks Small Cap Research

Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

LEXX: Phase I Start Imminent

Zacks Small Cap Research

BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LEXXW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LEXXW"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXXW\",,,,,undefined,":{"symbol":"LEXXW","market":"US","secType":"STK","nameCN":"Lexaria Bioscience Corp","latestPrice":0.2022,"timestamp":1741875124946,"preClose":0.24,"halted":0,"volume":104,"delay":0,"changeRate":-0.1575,"change":-0.0378,"floatShares":5104300,"shares":5104300,"lyrEps":0,"pbRate":0.11,"amount":21.020399920000003,"amplitude":0,"volumeRatio":0.319942,"dividePrice":0,"prevYearClose":0.7641,"fiveDayClose":0.2399,"twentyDayClose":0.24},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXXW\",,,,,undefined,":{"symbol":"LEXXW","floatShares":5104300,"roa":"-67.50%","roe":"-114.83%","lyrEps":0,"volumeRatio":0.319942,"shares":5104300,"dividePrice":0,"high":0.2022,"amplitude":0,"preClose":0.24,"low":0.2022,"week52Low":0.16,"pbRate":"0.11","psRate":"2.08","week52High":2.07,"institutionHeld":0,"latestPrice":0.2022,"committee":-0.399027,"eps":0,"divideRate":0,"volume":104,"delay":0,"ttmEps":0,"open":0.2022,"prevYearClose":0.7641,"prevWeekClose":0.23,"prevMonthClose":0.249,"prevQuarterClose":0.7641,"fiveDayClose":0.2399,"twentyDayClose":0.24,"sixtyDayClose":0.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LEXXW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LEXXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LEXXW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LEXXW\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514804509","title":"The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2514804509","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514804509?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:00","pubTimestamp":1740661200,"startTime":"0","endTime":"0","summary":"Lexaria executing a triple-pronged strategy in obesity and diabetes. Semaglutide recently approved to treat chronic kidney disease. The GLP-1 industry is experiencing revolutionary advancements across multiple healthcare sectors. If there has ever been a class of drugs that could change the world - or is perhaps already changing the world - it would be GLP-1. As tens of millions of people around the world utilize these drugs in their pursuit of better health outcomes, there will of course be unwanted side effects and even negative health outcomes in some fraction of GLP-1 drug users. With that said, the benefits of these drugs overwhelmingly outweigh all of the currently known negative outcomes.As we noted on November 26, 2024, GLP-1 drugs are either approved for use, or are being investigated for use, in all of the following healthcare sectors:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/global-revolution-healthcare-driven-glp-130000643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","GLP","BK4590","LEXX","BK4144","BK4137","BK4007","LEXXW"],"gpt_icon":0},{"id":"2513972986","title":"Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm","url":"https://stock-news.laohu8.com/highlight/detail?id=2513972986","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513972986?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"5th study arm in 12-week Phase 1b Study receives lead clinical site approval. KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee  approval that was required before dosing can begin in the 5th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4,  in Australia.This news complements similar news issued on November 13, 2024, when initial lead clinical site HREC approval was received for the first 4 arms of the Study. The Company is pleased to have received all of the necessary lead clinical site approvals so quickly. Additional HREC approval is still pending for the other clinical sites, which is expected soon.The Study is progressing with both patient recruitment and dosing. The milestone of First Patient First Dose occurred in December 2024 as planned. As a reminder, the 5 Study arms are as follows:. This press release","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ethics-board-approval-received-dehydratech-130000223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","BK4144","BK4557","ACB","BK4590","ARM","LEXXW","LEXX","BK4007"],"gpt_icon":0},{"id":"2510385490","title":"Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2510385490","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510385490?lang=en_us&edition=fundamental","pubTime":"2025-02-11 21:00","pubTimestamp":1739278800,"startTime":"0","endTime":"0","summary":"KELOWNA, BC / ACCESS Newswire / February 11, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH enhanced processing technology related to the treatment of epilepsy.\"We are thrilled to have received broadened claims related to our proprietary DehydraTECH technology for the treatment of epilepsy,\" said Rich Christopher, CEO of Lexaria. \"Each of our patent awards enhances our ability to reach commercial criticality while providing enhanced value to our potential pharmaceutical partners and, ultimately, to patients.\". Lexaria has received its 5th and 6th US patents granted in its patent family #24, Compositions and Methods for Treating Epilepsy. These patents complement earlier research which indicated that DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-granted-two-dehydratech-patents-130000319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXXW","LEXX"],"gpt_icon":0},{"id":"2509771692","title":"Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=2509771692","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509771692?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:40","pubTimestamp":1738852800,"startTime":"0","endTime":"0","summary":"World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules. KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide  rodent biodistribution study .Distribution of a drug once it enters the body can provide vital clues as to the understanding of that drug's ability to bind with targeted receptor cells, avoid concentration at physical sites that might be prone to fostering adverse side effects, and increase the drug's ultimate efficacy. Lexaria hopes to discover whether the DehydraTECH processing of semaglutide improves its biodistribution in any significant way compared to the conventional orally administered semaglutide formulation practice.DehydraTECH is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients  enter the bloodstream ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-biodistribution-study-dehydratech-glp-144000532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4590","LEXX","BK4144","GLP","LEXXW"],"gpt_icon":0},{"id":"2509810452","title":"Lexaria Updates its Ongoing Human Study GLP-1-H24-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2509810452","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509810452?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:10","pubTimestamp":1738764600,"startTime":"0","endTime":"0","summary":"Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss. KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to provide progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4  underway in Australia.Lexaria has completed its submission to the human research ethics committee  for its planned addition of Study Arm 5 to evaluate performance of its DehydraTECH-tirzepatide formulation, pursuant to the positive findings it previously achieved and released for Human Pilot Study #3 .Arms 2 and 3 of the Study are using DehydraTECH-processed pure semaglutide and will be compared to Study Arm 4 which will use Rybelsus tablets  that contains Novo Nordisk's proprietary salcoprozate sodium","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-updates-ongoing-human-study-141000535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4141","BK4590","LU0348723411.USD","BK4007","BK4585","IE00BMPRXR70.SGD","IE00BMPRXQ63.HKD","BK4557","ACB","BK4543","IE00BMPRXN33.USD","LEXX","BK4588","GLP","LEXXW","BK4144"],"gpt_icon":1},{"id":"2507215886","title":"Lexaria Releases Annual Letter from the CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507215886","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507215886?lang=en_us&edition=fundamental","pubTime":"2025-01-30 22:15","pubTimestamp":1738246500,"startTime":"0","endTime":"0","summary":"KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , , a global innovator in drug delivery platforms is pleased to provide this annual letter from its Chief Executive Officer  Richard Christopher as a strategic update to all stakeholders.In 2024, Lexaria made the course changing commitment to becoming an oral based drug delivery enabling technology company focused on one of the largest and fastest growing drug sectors in the world today - GLP-1. To that end, we conducted a series of human and animal studies which produced extremely encouraging pharmacokinetic, weight, blood glucose, insulin, and safety results. The success of these studies is a true testament to the effectiveness, versatility, and promise of our proprietary DehydraTECHTM technology platform within, and outside of, GLP-1.2024 R&D ResultsIn 2024, Lexaria spent virtually all of its time and efforts on conducting a series of human and animal studies which utilized our DehydraTECH technology with th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-releases-annual-letter-ceo-141500696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","BK4588","BK4557","ACB","LEXX","XBI","BK4007","BK4585","LEXXW"],"gpt_icon":0},{"id":"2506512605","title":"LEXX: IRB Approval Clears Way for GLP-1 Study #5","url":"https://stock-news.laohu8.com/highlight/detail?id=2506512605","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506512605?lang=en_us&edition=fundamental","pubTime":"2025-01-28 17:47","pubTimestamp":1738057620,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience Corporation  reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the Phase Ib trial evaluating DehydraTECH in obese patients. Several new patents were granted bringing the corporate total to 43.So far, Lexaria has been able to achieve impressive bioavailability and reach therapeutic drug levels in the blood plasma faster while reducing side effects using DehydraTECH formulations of the leading GLP-1 agonists compared with their approved infused formulations. With sponsors seeking the next generation of weight loss products and opportunities for life cycle management, Lexaria’s DehydraTECH formulations provide an answer. As the company continues its third and fourth human study in the class and prepares to launch its fifth, management is reaching out to potential partners who may be interested in further analysis and licensing opportunities.Research and development expenses tot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexx-irb-approval-clears-way-094700718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","DHT","LEXXW","BK4590","BK4144","LEXX","GLP"],"gpt_icon":0},{"id":"2503628951","title":"Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2503628951","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503628951?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:20","pubTimestamp":1736950800,"startTime":"0","endTime":"0","summary":"Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format. KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to announce that it has received the necessary independent ethics board approval required for its contract research organization  to begin to implement and execute human pilot study GLP-1-H25-5 . The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda  to the conventional injected liraglutide .The Study protocol design is complete and a clinical test site has been d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-human-glp-1-study-142000335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","GLP","LEXXW","LEXX","BK4590"],"gpt_icon":0},{"id":"2503579396","title":"Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503579396","media":"ACCESSWIRE","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503579396?lang=en_us&edition=fundamental","pubTime":"2025-01-14 22:10","pubTimestamp":1736863800,"startTime":"0","endTime":"0","summary":"Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound. Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound. KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3 , comparing an oral version of DehydraTECH-processed Zepbound  to conventional injected Zepbound.\"Lexaria is delighted, in our first-ever attempt to render a competitive version of an orally deliverable tirzepatide formulation, to have already achieved approximate parity in effectiveness with apparent superiority in tolerability to the advanced commercial, injected version of Zepbound already on the market,\" said Richard Christopher, CEO of Lexaria. \"We plan to continue to optimize dosing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexarias-oral-dehydratech-tirzepatide-reduces-141000300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0061475181.USD","LU1093756325.SGD","LU2602419157.SGD","SGXZ31699556.SGD","LU1868836914.USD","SG9999017495.SGD","LEXX","LU0122379950.USD","IE00B1BXHZ80.USD","IE0002141913.USD","LU1069344957.HKD","LU0385154629.USD","LU2361044865.SGD","SG9999015945.SGD","SGXZ57979304.SGD","LEXXW","LU0882574055.USD","LU1267930730.SGD","IE00B4R5TH58.HKD","LU0289739699.SGD","LU1291159041.SGD","BK4599","LU0320765059.SGD","SGXZ81514606.USD","LU1623119135.USD","LU0823416689.USD","LU0058720904.USD","R","GLP","LU0256863902.USD","IE00BJJMRZ35.SGD","SG9999014898.SGD","LU0471298777.SGD","SG9999013999.USD","LU0079474960.USD","LU2237443978.SGD","LU2264538146.SGD","LU2265009873.SGD","BK4581","LU2106854487.HKD","LU2324357040.USD","LLY","LU1868836757.USD","LU2461242641.AUD","BK4144","SGXZ99366536.SGD","IE00BJT1NW94.SGD","LU0417517546.SGD","LU1023059063.AUD","IE00BJLML261.HKD"],"gpt_icon":1},{"id":"2503239375","title":"Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2503239375","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503239375?lang=en_us&edition=fundamental","pubTime":"2025-01-14 18:49","pubTimestamp":1736851786,"startTime":"0","endTime":"0","summary":"NasdaqCM:LEXX Earnings and Revenue History January 14th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 84%. Earnings per share  missed analyst estimates by 33%.Looking ahead, revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in the US.The company's shares are down 5.5% from a week ago.Before you take the next step you should know about the 4 warning signs for Lexaria Bioscience (2 are significant!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-bioscience-first-quarter-2025-104946203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXXW","LEXX"],"gpt_icon":0},{"id":"2492171671","title":"Lexaria's Registered GLP-1 Study #4 Begins Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2492171671","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492171671?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:05","pubTimestamp":1734617100,"startTime":"0","endTime":"0","summary":"Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss. KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, . The Study is designed mainly to determine whether Lexaria's proprietary DehydraTECH technology improves the safety and effectiveness of existing GLP-1 drugs.\"Achieving the first patient, first dose Study milestone is a critical achievement,\" said John Docherty, President and Chief Scientific Officer of Lexaria Bioscience Corp. \"The world's first 12-week human study evaluating DehydraTECH-processed GLP-1 drugs, in addition to DehydraTECH-CBD, in pre-diabetics or diabetic patients is underway. Potential benefits of reduced side-effects and improved efficacy could be evidenced.\". Arm 1 of the Study will utilize a proprietary, patented DehydraTECH-CBD formulation. Our 2022 diabetes ani","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexarias-registered-glp-1-study-140500420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","LEXXW","IE00BMPRXQ63.HKD","BK4557","IE00BMPRXR70.SGD","BK4585","IE00BMPRXN33.USD","LEXX","BK4144","BK4007","ACB","LU0348723411.USD","BK4590","BK4588","BK4141"],"gpt_icon":1},{"id":"2492848061","title":"Lexaria Forms New Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2492848061","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492848061?lang=en_us&edition=fundamental","pubTime":"2024-12-18 22:25","pubTimestamp":1734531900,"startTime":"0","endTime":"0","summary":"North American drug delivery development experts added to help guide Lexaria's strategic plans. KELOWNA, BC / ACCESSWIRE / December 18, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces the creation of its new Scientific Advisory Board  to assist in guiding Lexaria's rapid drug delivery platform technology and strategic development plans within the pharmaceutical industry.Lexaria's SAB has been carefully constituted with the following members to provide expertise in the key areas of pharmaceutical development spanning clinical and preclinical testing, as well as Chemistry Manufacturing and Controls  characterization and validation; all of which are vital components of the highly regulated processes of advancing drug and delivery technology programs through to commercialization:","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-forms-scientific-advisory-board-142500523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LEXX","LEXXW"],"gpt_icon":0},{"id":"2492968023","title":"Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2492968023","media":"ACCESSWIRE","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492968023?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:10","pubTimestamp":1734444600,"startTime":"0","endTime":"0","summary":"Dr. Gibson joining Lexaria's new scientific advisor board. KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria's patented DehydraTECH drug delivery platform continues to expand its applications in GLP-1 and hypertension.C. Michael Gibson M.S., M.D., is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. Gibson founded PERFUSE in 1987 which served as the TIMI Data coordinating center that coordinated data for the first 50 TIMI trials. The Baim institute was formerly known as Harvard Clinical Research Institute and was founded in 2000.As Chief Medical Advisor, Dr. Gibson will participate with other scientific and medical experts within Lexari","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/esteemed-harvard-medical-school-professor-141000137.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXXW","BK4007","LEXX"],"gpt_icon":0},{"id":"2490577371","title":"Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5","url":"https://stock-news.laohu8.com/highlight/detail?id=2490577371","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490577371?lang=en_us&edition=fundamental","pubTime":"2024-12-09 22:10","pubTimestamp":1733753400,"startTime":"0","endTime":"0","summary":"Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide. KELOWNA, BC / ACCESSWIRE / December 9, 2024 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to announce the engagement of a contract research organization  to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda injectable liraglutide.As reported on November 20th in Lexaria's 12-week rodent study with unlimited food available, DehydraTECH-processed liraglutide - administered orally - demonstrated a 5.88% weight reduction and 11.54% blood sugar reduction compared to baseline. The Rybelsus  control, which was expected to outperform liraglutide, instead produced a 5.65% increase in body weight and 0.41% blood sugar reduction compared to baseline during the same 12 weeks.As a result of the stronger than expected performance of DehydraTECH-processed liraglutide, the Company has made the decision to i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FJePO2ijjHG5xb7IgCEAtw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/125bab67eda29e558483e26b3c7ebbdc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/liraglutide-processed-dehydratech-studied-human-141000375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","LEXX","GLP","LEXXW","BK4590"],"gpt_icon":0},{"id":"2489629274","title":"LEXX: Phase I Start Imminent","url":"https://stock-news.laohu8.com/highlight/detail?id=2489629274","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489629274?lang=en_us&edition=fundamental","pubTime":"2024-12-05 19:15","pubTimestamp":1733397300,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience Corporation  reported fiscal third 2024 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the Phase Ib trial evaluating DehydraTECH in obese patients. Several new patents were granted bringing the total to 43. Lexaria’s primary focus for fiscal 2024 was to demonstrate that DehydraTECH  can be an effective delivery system serving the burgeoning GLP-1 agonist space. Oral options for GLP-1s are limited and initial data for DHT-GLP-1s promising leading to the development of a series of studies that seek to find the best approach for a more convenient delivery method. At the end of August, Lexaria completed its 2024 fiscal year and reported these results at the end of November. We summarize the results below.Lexaria filed its 2024 Form 10-K on November 26th, 2024. The company reported FY 2024 revenues of $464,000, and total operating expense of $6.2 million resulting in net loss of  million or  per diluted common ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Mp_Fa5DFH7PuFiLoGgWpJg--~B/aD04ODY7dz0xMzYyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/9843c2749db06147b1cb8e87941c5dce","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Mp_Fa5DFH7PuFiLoGgWpJg--~B/aD04ODY7dz0xMzYyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/9843c2749db06147b1cb8e87941c5dce"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexx-phase-start-imminent-111500537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4144","ACB","LEXX","LEXXW","DHT","BK4557"],"gpt_icon":0},{"id":"2488503916","title":"BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals","url":"https://stock-news.laohu8.com/highlight/detail?id=2488503916","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488503916?lang=en_us&edition=fundamental","pubTime":"2024-12-01 00:00","pubTimestamp":1732982400,"startTime":"0","endTime":"0","summary":"Vancouver, British Columbia-- - On FOX Business News broadcast on Sunday, Dec 1, 2024 - BTV Business Television interviews emerging companies in the markets including:. Contango ORE, Inc.  - Redefining modern gold mining, Contango ORE has achieved remarkable efficiency through its hybrid royalty model and strategic partnerships. Leveraging existing infrastructure to minimize environmental impact, the company accelerates production timelines and optimizes costs.First Nordic Metals   - Backed by a recent $10 million bought deal financing and a commitment to operational excellence in Sweden and Finland, First Nordic Metals has a combined resource of over 2.7 million ounces of gold and strong partnerships.Prime Mining Corp.   - Focused on resource expansion and technical de-risking, Prime Mining is poised to support the growing demand for sustainable and scalable mining solutions, solidifying its position in the global precious metals sector.West Red Lake Gold Mines Ltd.  - is set to resta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/btv-features-stocks-watch-contango-160000512.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/btv-features-stocks-watch-contango-160000512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXX","ODV","CIAFF","BK4006","CTGO","PRMNF","BK4168","BK4007","BK4017","LEXXW","FNMCF"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":1,"totalSize":31}]}}